TheraRadar
Clinical-Stage Companies / Veru

Veru

Pre-Approval PRO BETA
12
Total Trials
4
Phase 3
8
Phase 2
1
Recruiting
135
Score

Pipeline by Phase

Phase 3
4
Phase 2
8
Phase 1
2

Therapeutic Focus

Metastatic Breast Cancer Obesity & Overweight Mobility Disability HOMA-IR Muscle Loss

Clinical Trials (12)

NCT05065411 Phase 3 TERMINATED

Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

Started: 4/11/2022

NCT04844749 Phase 3 TERMINATED

Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Started: 6/24/2021

NCT04869943 Phase 3 TERMINATED

Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

Started: 10/12/2021

NCT04842747 Phase 3 COMPLETED

VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study

Started: 5/18/2021

NCT07446998 Phase 2 RECRUITING

Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss

Started: 3/26/2026

NCT06282458 Phase 2 COMPLETED

Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt

Started: 4/29/2024

NCT05079360 Phase 2 WITHDRAWN

Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

Started: 3/15/2023

NCT04388826 Phase 2 COMPLETED

COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111

Started: 6/18/2020

NCT05008510 Phase 2 WITHDRAWN

P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .

Started: 12/30/2021

NCT03646162 Phase 2 COMPLETED

Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer

Started: 9/14/2018

NCT03752099 Phase 1 TERMINATED

To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer

Started: 1/18/2019

NCT04843319 Phase 1 TERMINATED

To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer

Started: 6/9/2021

Drug Candidates

Enobosarm Semaglutide (Wegovy) weekly injection Semaglutide Enobosarm & Abemaciclib Combo non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant VERU-111 Enzalutamide, Abiraterone Exemestane VERU-100 Sabizabulin
Activity Status: Active
Last Trial Started: 3/26/2026
Last Trial Ended: 8/22/2025
Trials (12 months): 1
Completed Trials: 4
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.